New drug trial aims to outperform standard lung cancer treatment
NCT ID NCT07360132
Summary
This study is testing if a new drug, HB0025, works better than the current standard drug, pembrolizumab, when each is given with chemotherapy. It is for adults with advanced or metastatic squamous non-small cell lung cancer who have not had prior treatment. About 480 participants will be randomly assigned to one of the two treatment groups to compare how long the cancer is kept from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.